*Monthly rates reflect plan length: $89/mo billed $267 every 3 months, $79/mo billed $474 every 6 months, $69/mo billed $828 every 12 months
X-linked Charcot-Marie-Tooth disease and progressive-relapsing central demyelinating disease
As shown in Table 168, for the six specialty groups that account for the most ASC utilization and spending, we estimate that the final update to ASC payment rates for CY 2026 would result in a 4 percent increase in aggregate payment amounts for eye and ocular adnexa procedures, a 2 percent increase in aggregate payment amounts for musculoskeletal system procedures, a 2 percent increase in aggregate payment amounts for nervous system procedures, a 3 percent increase in aggregate payment amounts for digestive system procedures, a 5 percent increase in aggregate payment amounts for cardiovascular system procedures, and a 12 percent increase in aggregate payment amounts for genitourinary system procedures
The combined index diagnostic model constructed based on these indicators demonstrated strong discriminatory power, with an area under the receiver operating characteristic (ROC) curve of 0.943, a sensitivity of 92.6%, and a specificity of 93.7%
Self-reported dose per injection Median bucket: 0.20.4 mg Most common: 0.20.4 mg Reports span 0.1 to 5 mg (open-ended top bucket) Anonymized self-reports from PeptIQ users not prescribing guidance
